Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-09-08
2009-02-24
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07494981
ABSTRACT:
PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining the MAC of inhalational anesthetics. Suppression of the expression of PSD-95/SAP90 in the spinal cord significantly attenuates responses to painful stimuli mediated through the N-methyl-D-aspartate receptor activation. In spinal cord neurons PSD-95/SAP90 interacts with the N-methyl-D-aspartate receptor subunits 2A/2B. Activation of the N-methyl-D-aspartate receptor in spinal hyperalgesia results in association of the N-methyl-D-aspartate receptor with PSD-95/SAP90. PSD-95/SAP90 is required for hyperalgesia triggered via the N-methyl-D-aspartate receptor at the spinal cord level.
REFERENCES:
patent: 5877309 (1999-03-01), McKay et al.
patent: 2273622 (2000-12-01), None
patent: WO 97/33173 (1997-09-01), None
patent: WO 97/46877 (1997-12-01), None
patent: WO 99/37768 (1999-07-01), None
Harris and Lim, J. Cell Science 114: 3219-3231, 2001.
Stein, C.A., Pharmacol. and Therap. 85: 231-236, 2000.
Jen et al., Stem Cells 18: 307-319, 2000.
Chirila et al, January, Biomaterials 23:321-342, 2002.
Chizh and Headley, Curr. Pharm. Design 11(23): 2977-2994, 2005.
Wheal et al, Progress in Neurobiology 55(6), 1998; pp. 611 and 627.
J. Neurobiology 66(11): 1195-1211, 2006.
Stathakis et al, Genomics 44(1): 71-82, 1997.
Manev et al, Life Sciences 76(21): 2403-2407, 2005.
Tao et al. NeuroReport, 2001 vol. 12:3251-3255.
Tao et al. Neuroscience, 2000 vol. 98 :201-206.
Tao et al. Anesthesiology, 2001 vol. 94:1010-1015.
Agrawal, S. TIBTech, 1996 Voll 14:376-387.
Agrawal et al. Molecular Medicine Today, 2000 vol. 6:72-81.
Tamm et al. The Lancet., 2001, vol. 358:489-497.
Nielsen, PE Gene Therapy, 2005 vol. 12:956-957.
Woolf C.J., et al.,Pain, “The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activiation; implications for the treatment of post-injury pain hypersensitivity states”, 44, pp. 293-299 (1991).
Ishizaki, K. et al.,Can. J. Anesth., “Intrathecally administered NMDA receptor antagonists reduce the MAC of isoflurane in rats”, 43:7, pp. 724-730 (1996).
Sattler, R., et al.,Science, “Specific coupling of NMDA receptor activiation to nitric oxide neurotoxicity by PSD-95 protein”, 284, pp. 1845-1848 (1999).
Brenman, J.E., et al.,The Journal of Neuroscience, “Cloning and characterization of postsynaptic Density 93, a nitric oxide synthase interacting protein”, 16(23), pp. 7407-7415 (1996).
Tao, F. et al.,Neuroreport, “Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats”, 12:15, pp. 3251-3255 (2001).
Tao, Y-X., et al.,Anesthesiology, “Effect of the deficiency of spinal PSD95/SAP90 on the minimum alveotar anesthetic concentration of isoflurance in rats”, 94:6, pp. 1010-1015 (2001).
Chih-Ling Choi and Scheherazade Sadegh-Nasseri, “HLA-DM Recognizes the Flexible Conformation of Major Histocompatibilty Complex Class II”, The Rockefeller University Press, J. Exp. Med.,vol. 192, No. 12, 2000, pp. 1697-1706.
L. N. Maganas and J. S. Trimmer; “Subunit Composition Determines Kv1 Potassium Channel Surface Expression”, The Journal of Biological Chemistry, vol. 275, No. 38, 2000, pp. 29685-29693.
Rita Sattler, Zhigang Xiong, Wei-Yang Lu, Mathias Hafner, John F. MacDonald and Michale Tymianski; “Specific Coupling of NMDA Receptor Activation to Nitric Oxide Neurotoxicity by PSD-95 Protein”, Science vol. 284, 1999, pp. 1845-1848.
Y.-X. Tao, Y.-Z. Huang, L. Mei and R. A. Johns, “Expression of PSD-95/SAP90 is Critical forN-Methyl-D-Aspartate Receptor-Mediated Thermal Hyperalgesia in the Spinal Cord”, Neuroscience, vol. 98, No. 2, 2000, pp. 201-206.
M. Migaud, P. Charlesworth, M. Dempster, L. Webster, A. Watabe, M. Makhinson, Y. He, M. Ramey, R. Morris, J. Morrison, T. O'Dell and S. Grant, “Enhanced Long-Term Potentiation and Imparied Learning in Mice with Mutant Postsynaptic Density-95 Protein”, Nature, vol. 396, 1998, pp. 433-439.
Chen et al., “A Safety and Pharmacokinetic Study of a Mixed-Backbone Oligonucleotide (GEM231) Targeting the Type I Protein Kinase A by Two-hour Infusions in Patients with Refractory Solid Tumors,”Clin. Cancer Research 6, 1259-66, Apr. 2000.
Clark et al., “Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia,”Bone Marrow Transplantation 23, 1303-08, 1999.
Cunningham et al., “A Phase I Trial ofc-RafKinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer,”Clin. Cancer Res. 6, 1626-31, May 2000.
de Smet et al., “Fomivirsen—a phosphorothioate oligonucleotide for the treatment of CMV retinitis,”Ocul. Immunol. Inflamm. 7, 189-98, Dec. 1999 (abstract).
Gewirtz, “Myb targeted therapeutics for the treatment of human malignancies,”Oncogene 18, 3056-62, May 13, 1999 (abstract).
Glover et al., “Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS-2302),”J. Pharmacol. Exptl. Ther. 282, 1173-80, 1997.
Nemunaitis et al., “Phase I Evaluation of ISIS 3521, an antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer,”J. Clin. Oncol. 17, 3586-95, Nov. 1999.
O'Dwyer et al., “c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A),”Clin. Cancer Res. 5, 3977-82, Dec. 1999.
Sereni et al., “Pharmacokinetics and tolerability of intravenous trecorvirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects,”J. Clin. Pharmacol 39, 47-54, Jan. 1999 (abstract).
Stevenson et al., “Phase I clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A),”J. Clin. Oncol. 17, 2227-36, Jul. 1999.
Waters et al., “Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma,”J. Clin. Oncol. 18, 1812-23, May 2000.
Yuen et al., “Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A) in Patients with Cancer,”Clin. Cancer Res. 5, 3357-63, Nov. 1999.
Bjergård & Dahl, “Solid phase synthesis of oligodeoxyribonucleoside phosphorodithioates from thiophosphoramidites,”Nucl. Acids Res. 19, 5843-50, 1991.
Hirashima et al., “Artificial Immune System against Viral Infection Involving antisense RNA Targeted to the 5′-Terminal Noncoding Region of Coliphage SP RNA,”J. Biochem. 106, 163-66 (1989).
Parker et al., “Targeted Gene Walking Polymerase Chain Reaction,”Nucl. Acids Res. 19, 3055-60, 1991.
Shuttleworth & Colman, “Antisense oligonucleotide-directed cleavage of mRNA inXenopusoocytes and eggs,”EMBO Journal 7, 427-34, 1988.
Stein & Cohen, “Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review,”Cancer Res. 48, 2659-68, May 15, 1988.
Johns Roger
Tao Yuanxiang
Banner & Witcoff , Ltd.
Gibbs Terra Cotta
McGarry Sean
The Johns Hopkins University
LandOfFree
Inhibition of interaction of PSD93 and PSD95 with nNOS and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of interaction of PSD93 and PSD95 with nNOS and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of interaction of PSD93 and PSD95 with nNOS and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075707